Alexandros Makriyannis

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Phenomena

Magnetic Resonance Spectroscopy

Co-author Network

Publications

TOP 3
Jenny L Wilkerson; Katherine R Gentry; Ellen C Dengler; James A Wallace; Audra A Kerwin; Leisha M Armijo; Megan N Kuhn; Ganesh A Thakur; Alexandros Makriyannis; Erin D Milligan
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels.
Maria Scherma; Zuzana Justinová; Claudio Zanettini; Leigh V Panlilio; Paola Mascia; Paola Fadda; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Islam Gamaleddin; et al.
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats.
Jenny L Wilkerson; Katherine R Gentry; Ellen C Dengler; James A Wallace; Audra A Kerwin; Megan N Kuhn; Alexander M Zvonok; Ganesh A Thakur; Alexandros Makriyannis; Erin D Milligan
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alexandros Makriyannis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jenny L Wilkerson; Katherine R Gentry; Ellen C Dengler; James A Wallace; Audra A Kerwin; Leisha M Armijo; Megan N Kuhn; Ganesh A Thakur; Alexandros Makriyannis; Erin D Milligan
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels.
Pain 2012;153(5):1091-106.
2012: Maria Scherma; Zuzana Justinová; Claudio Zanettini; Leigh V Panlilio; Paola Mascia; Paola Fadda; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Islam Gamaleddin; et al.
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats.
British journal of pharmacology 2012;165(8):2539-48.
2012: Jenny L Wilkerson; Katherine R Gentry; Ellen C Dengler; James A Wallace; Audra A Kerwin; Megan N Kuhn; Alexander M Zvonok; Ganesh A Thakur; Alexandros Makriyannis; Erin D Milligan
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.
Brain and behavior 2012;2(2):155-77.
2012: Vedrana Reichenbach; Josefa Ros; Guillermo Fernández-Varo; Gregori Casals; Pedro Melgar-Lesmes; Teresa Campos; Alexandros Makriyannis; Manuel Morales-Ruiz; Wladimiro Jiménez
Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems.
The Journal of pharmacology and experimental therapeutics 2012;340(3):629-37.
2012: Torbjörn U C Järbe; Sherrica Tai; Brian J LeMay; Spyros P Nikas; Vidyanand G Shukla; Alexander Zvonok; Alexandros Makriyannis
AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.
Psychopharmacology 2012;220(2):417-26.
2012: M Bashashati; M A Storr; S P Nikas; J T Wood; G Godlewski; J Liu; W Ho; C M Keenan; H Zhang; S O Alapafuja; et al.
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.
British journal of pharmacology 2012;165(5):1556-71.
2012: Jay M West; Nikolai Zvonok; Kyle M Whitten; Jodianne T Wood; Alexandros Makriyannis
Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase.
Journal of proteome research 2012;11(2):972-81.
2012: Islam Gamaleddin; Alexander Zvonok; Alexandros Makriyannis; Steven R Goldberg; Bernard Le Foll
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking.
PloS one 2012;7(1):e29900.
2011: Alexandros Makriyannis; Spyros P Nikas
Aspirin-triggered metabolites of EFAs.
Chemistry & biology 2011;18(10):1208-9.
2011: Dennis W Szymanski; Malvina Papanastasiou; Katja Melchior; Nikolai Zvonok; Richard W Mercier; David R Janero; Ganesh A Thakur; Sangwon Cha; Billy Wu; Barry Karger; et al.
Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.
Journal of proteome research 2011;10(10):4789-98.
2011: Heidi Teng; Ganesh A Thakur; Alexandros Makriyannis
Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
Bioorganic & medicinal chemistry letters 2011;21(19):5999-6002.
2011: Torbjörn U C Järbe; Hongfen Deng; Subramanian K Vadivel; Alexandros Makriyannis
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.
Behavioural pharmacology 2011;22(5-6):498-507.
2011: Tannia Gutierrez; Jonathon D Crystal; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Self-medication of a cannabinoid CB(2) agonist in an animal model of neuropathic pain.
Pain 2011;152(9):1976-87.
2011: Xiaoyu Tian; Spiro Pavlopoulos; De-Ping Yang; Alexandros Makriyannis
The interaction of cannabinoid receptor agonists, CP55940 and WIN55212-2 with membranes using solid state 2H NMR.
Biochimica et biophysica acta 2011;1808(9):2095-101.
2011: Torbjörn U C Järbe; Brian J LeMay; V Kiran Vemuri; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Psychopharmacology 2011;216(3):355-65.
2011: Elizabeth J Rahn; Ganesh A Thakur; Jodi Anne T Wood; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.
Pharmacology, biochemistry, and behavior 2011;98(4):493-502.
2011: Richard I Duclos; Meghan Johnston; Subramanian K Vadivel; Alexandros Makriyannis; Sherrye T Glaser; S John Gatley
A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG).
The Journal of organic chemistry 2011;76(7):2049-55.
2011: Shubhadra N Singh; Kunal Bakshi; Richard W Mercier; Alexandros Makriyannis; Spiro Pavlopoulos
Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2.
Biochemistry 2011;50(12):2223-34.
2011: Elvis K Tiburu; Sergiy Tyukhtenko; Han Zhou; David R Janero; Jochem Struppe; Alexandros Makriyannis
Human cannabinoid 1 GPCR C-terminal domain interacts with bilayer phospholipids to modulate the structure of its membrane environment.
The AAPS journal 2011;13(1):92-8.
2011: Vinogran Naidoo; Spyros P Nikas; David A Karanian; Jeannie Hwang; Jianhong Zhao; JodiAnne T Wood; Shakiru O Alapafuja; Subramanian K Vadivel; David Butler; Alexandros Makriyannis; et al.
A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.
Journal of molecular neuroscience : MN 2011;43(3):493-502.
2011: Shuxian Jiang; Meritxell Alberich-Jorda; Radoslaw Zagozdzon; Kalindi Parmar; Yigong Fu; Peter Mauch; Naheed Banu; Alexandros Makriyannis; Daniel G Tenen; Shalom Avraham; et al.
Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization.
Blood 2011;117(3):827-38.
2011: Nina L Cluny; Adam P Chambers; V Kiran Vemuri; Jodianne T Wood; Lindsay K Eller; Carmelina Freni; Raylene A Reimer; Alexandros Makriyannis; Keith A Sharkey
The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.
Pharmacology, biochemistry, and behavior 2011;97(3):537-43.
2010: Torbjörn U C Järbe; Roger S Gifford; Alexandros Makriyannis
Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
European journal of pharmacology 2010;648(1-3):133-8.
2010: Grzegorz Godlewski; Shakiru O Alapafuja; Sándor Bátkai; Spyros P Nikas; Resat Cinar; László Offertáler; Douglas Osei-Hyiaman; Jie Liu; Bani Mukhopadhyay; Judith Harvey-White; et al.
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.
Chemistry & biology 2010;17(11):1256-66.
2010: Shuxian Jiang; Radoslaw Zagozdzon; Meritxell Alberich Jorda; Kalindi Parmar; Yigong Fu; John S Williams; Jodi Anne T Wood; Alexandros Makriyannis; Naheed Banu; Shalom Avraham; et al.
Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.
The Journal of biological chemistry 2010;285(46):35471-8.
2010: P A Randall; V K Vemuri; K N Segovia; E Ferreris Torres; S Hosmer; E J Nunes; J L Santerre; A Makriyannis; J D Salamone
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior.
Pharmacology, biochemistry, and behavior 2010;97(1):179-84.
2010: Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.
Chemistry & biology 2010;17(10):1132-42.
2010: Spyros P Nikas; Shakiru O Alapafuja; Ioannis Papanastasiou; Carol A Paronis; Vidyanand G Shukla; Demetris P Papahatjis; Anna L Bowman; Aneetha Halikhedkar; Xiuwen Han; Alexandros Makriyannis
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.
Journal of medicinal chemistry 2010;53(19):6996-7010.
2010: N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; et al.
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
British journal of pharmacology 2010;161(3):629-42.
2010: Jayaraman Selvakumar; Alexandros Makriyannis; Chinnasamy Ramaraj Ramanathan
An unusual reactivity of BBr(3): Accessing tetrahydroisoquinoline units from N-phenethylimides.
Organic & biomolecular chemistry 2010;8(18):4056-8.
2010: Kodumuru Vishnumurthy; Alexandros Makriyannis
Novel and efficient one-step parallel synthesis of dibenzopyranones via Suzuki-Miyaura cross coupling.
Journal of combinatorial chemistry 2010;12(5):664-9.
2010: Darryl D Dixon; Divakaramenon Sethumadhavan; Tore Benneche; April R Banaag; Marcus A Tius; Ganesh A Thakur; Anna Bowman; Jodianne T Wood; Alexandros Makriyannis
Heteroadamantyl cannabinoids.
Journal of medicinal chemistry 2010;53(15):5656-66.
2010: Joseph Tam; V Kiran Vemuri; Jie Liu; Sándor Bátkai; Bani Mukhopadhyay; Grzegorz Godlewski; Douglas Osei-Hyiaman; Shinobu Ohnuma; Suresh V Ambudkar; James Pickel; et al.
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
The Journal of clinical investigation 2010;120(8):2953-66.
2010: Ioannis Karageorgos; Sergiy Tyukhtenko; Nikolai Zvonok; David R Janero; Christine Sallum; Alexandros Makriyannis
Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.
Molecular bioSystems 2010;6(8):1381-8.
2010: P J McLaughlin; K M Winston; L A Swezey; V K Vemuri; A Makriyannis; J D Salamone
Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.
Pharmacology, biochemistry, and behavior 2010;96(1):75-81.
2010: M A Storr; M Bashashati; C Hirota; V K Vemuri; C M Keenan; M Duncan; B Lutz; K Mackie; A Makriyannis; W K Macnaughton; et al.
Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2010;22(7):787-96, e223.
2010: Dimitris Anagnostopoulos; Carmelina Rakiec; Jodi Wood; Lakshmipathi Pandarinathan; Nikolai Zvonok; Alexandros Makriyannis; Athanasia Siafaka-Kapadai
Identification of endocannabinoids and related N-acylethanolamines in tetrahymena. A new class of compounds for Tetrahymena.
Protist 2010;161(3):452-65.
2010: K S Sink; K N Segovia; L E Collins; E J Markus; V K Vemuri; A Makriyannis; J D Salamone
The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats.
Pharmacology, biochemistry, and behavior 2010;95(4):479-84.
2010: Elizabeth J Rahn; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.
The AAPS journal 2010;12(2):147-57.
2010: Jodianne T Wood; John S Williams; Lakshmipathi Pandarinathan; David R Janero; Carol J Lammi-Keefe; Alexandros Makriyannis
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.
Journal of lipid research 2010;51(6):1416-23.
2010: Jeannie Hwang; Crista Adamson; David Butler; David R Janero; Alexandros Makriyannis; Ben A Bahr
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Life sciences 2010;86(15-16):615-23.
2010: Demetris P Papahatjis; Victoria R Nahmias; Spyros P Nikas; Marion Schimpgen; Alexandros Makriyannis
Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids.
Chemistry (Weinheim an der Bergstrasse, Germany) 2010;16(13):4091-9.
2010: Nikolai Zvonok; Wei Xu; John Williams; David R Janero; Srinivasan C Krishnan; Alexandros Makriyannis
Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor.
Journal of proteome research 2010;9(4):1746-53.
2010: Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol.
Psychopharmacology 2010;208(1):87-98.
2009: Sergiy Tyukhtenko; Elvis K Tiburu; Lalit Deshmukh; Olga Vinogradova; David R Janero; Alexandros Makriyannis
NMR solution structure of human cannabinoid receptor-1 helix 7/8 peptide: candidate electrostatic interactions and microdomain formation.
Biochemical and biophysical research communications 2009;390(3):441-6.
2009: Ganesh A Thakur; Ritesh Tichkule; Shama Bajaj; Alexandros Makriyannis
Latest advances in cannabinoid receptor agonists.
Expert opinion on therapeutic patents 2009;19(12):1647-73.
2009: Anna L Bowman; Alexandros Makriyannis
Refined homology model of monoacylglycerol lipase: toward a selective inhibitor.
Journal of computer-aided molecular design 2009;23(11):799-806.
2009: Martin A Storr; Catherine M Keenan; Hong Zhang; Kamala D Patel; Alexandros Makriyannis; Keith A Sharkey
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.
Inflammatory bowel diseases 2009;15(11):1678-85.
2009: K S Sink; K N Segovia; E J Nunes; L E Collins; V K Vemuri; G Thakur; A Makriyannis; J D Salamone
Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats.
Psychopharmacology 2009;206(2):223-32.
2009: Elvis K Tiburu; Sergiy Tyukhtenko; Lalit Deshmukh; Olga Vinogradova; David R Janero; Alexandros Makriyannis
Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments.
Biochemical and biophysical research communications 2009;384(2):243-8.
2009: Elvis K Tiburu; Stefano V Gulla; Mark Tiburu; David R Janero; David E Budil; Alexandros Makriyannis
Dynamic conformational responses of a human cannabinoid receptor-1 helix domain to its membrane environment.
Biochemistry 2009;48(22):4895-904.
2009: Elvis K Tiburu; Anna L Bowman; Jochem O Struppe; David R Janero; Hava K Avraham; Alexandros Makriyannis
Solid-state NMR and molecular dynamics characterization of cannabinoid receptor-1 (CB1) helix 7 conformational plasticity in model membranes.
Biochimica et biophysica acta 2009;1788(5):1159-67.
2009: David R Janero; Subramanian K Vadivel; Alexandros Makriyannis
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.
International review of psychiatry (Abingdon, England) 2009;21(2):122-33.
2009: Torbjörn U C Järbe; Chen Li; Qian Liu; Alexandros Makriyannis
Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.
Psychopharmacology 2009;203(2):229-39.
2009: David R Janero; Alexandros Makriyannis
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
Expert opinion on emerging drugs 2009;14(1):43-65.
2009: George Kunos; Douglas Osei-Hyiaman; Sándor Bátkai; Keith A Sharkey; Alexandros Makriyannis
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
Trends in pharmacological sciences 2009;30(1):1-7.
2008: Ying Pei; Richard W Mercier; Jenine K Anday; Ganesh A Thakur; Alexander M Zvonok; Dow Hurst; Patricia H Reggio; David R Janero; Alexandros Makriyannis
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
Chemistry & biology 2008;15(11):1207-19.
2008: Janel Hodge; Joshua P Bow; Kimberly S Plyler; V Kiran Vemuri; Ania Wisniecki; John D Salamone; Alexandros Makriyannis; Peter J McLaughlin
The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.
Behavioural brain research 2008;193(2):298-305.
2008: Fenmei Yao; Chen Li; Subramanian K Vadivel; Anna L Bowman; Alexandros Makriyannis
Development of novel tail-modified anandamide analogs.
Bioorganic & medicinal chemistry letters 2008;18(22):5912-5.
2008: Jianxin Guo; De-Ping Yang; Ravi Chari; Xiaoyu Tian; Spiro Pavlopoulos; Dai Lu; Alexandros Makriyannis
Magnetically aligned bicelles to study the orientation of lipophilic ligands in membrane bilayers.
Journal of medicinal chemistry 2008;51(21):6793-9.
2008: Tzong-Shi Lu; Hava Karsenty Avraham; Seyha Seng; Souvenir D Tachado; Henry Koziel; Alexandros Makriyannis; Shalom Avraham
Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6406-16.
2008: Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.
The Journal of pharmacology and experimental therapeutics 2008;327(2):584-91.
2008: T U C Järbe; B J LeMay; T Olszewska; V K Vemuri; J T Wood; A Makriyannis
Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Pharmacology, biochemistry, and behavior 2008;91(1):84-90.
2008: Dai Lu; Jianxin Guo; Richard I Duclos; Anna L Bowman; Alexandros Makriyannis
Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands.
Journal of medicinal chemistry 2008;51(20):6393-9.
2008: Victoria Magrioti; George Naxakis; Dimitra Hadjipavlou-Litina; Alexandros Makriyannis; George Kokotos
A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity.
Bioorganic & medicinal chemistry letters 2008;18(20):5424-7.
2008: Nikolai Zvonok; Lakshmipathi Pandarinathan; John Williams; Meghan Johnston; Ioannis Karageorgos; David R Janero; Srinivasan C Krishnan; Alexandros Makriyannis
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.
Chemistry & biology 2008;15(8):854-62.
2008: Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Psychopharmacology 2008;198(4):467-78.
2008: Nikolai Zvonok; John Williams; Meghan Johnston; Lakshmipathi Pandarinathan; David R Janero; Jing Li; Srinivasan C Krishnan; Alexandros Makriyannis
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification.
Journal of proteome research 2008;7(5):2158-64.
2008: Ankur Kapur; Patrick Samaniego; Ganesh A Thakur; Alexandros Makriyannis; Mary E Abood
Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
The Journal of pharmacology and experimental therapeutics 2008;325(1):341-8.
2008: V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Physiology & behavior 2008;93(4-5):671-86.
2008: K S Sink; V K Vemuri; T Olszewska; A Makriyannis; J D Salamone
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior.
Psychopharmacology 2008;196(4):565-74.
2008: Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; et al.
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(4):946-55.
2008: JodiAnne T Wood; John S Williams; Lakshmipathi Pandarinathan; Amber Courville; Melissa R Keplinger; David R Janero; Paul Vouros; Alexandros Makriyannis; Carol J Lammi-Keefe
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(9):1289-95.
2008: Maria Scherma; Julie Medalie; Walter Fratta; Subramanian K Vadivel; Alexandros Makriyannis; Daniele Piomelli; Eva Mikics; Jozsef Haller; Sevil Yasar; Gianluigi Tanda; et al.
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Neuropharmacology 2008;54(1):129-40.
2007: Atmaram D Khanolkar; Dai Lu; Mohab Ibrahim; Richard I Duclos; Ganesh A Thakur; T Phillip Malan; Frank Porreca; Vijayabaskar Veerappan; Xiaoyu Tian; Clifford George; et al.
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Journal of medicinal chemistry 2007;50(26):6493-500.
2007: Adam P Chambers; V Kiran Vemuri; Yan Peng; Jodianne T Wood; Teresa Olszewska; Quentin J Pittman; Alexandros Makriyannis; Keith A Sharkey
A neutral CB1 receptor antagonist reduces weight gain in rat.
American journal of physiology. Regulatory, integrative and comparative physiology 2007;293(6):R2185-93.
2007: Torbjörn U C Järbe; Nicholas V DiPatrizio; Chen Li; Alexandros Makriyannis
Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
Behavioural pharmacology 2007;18(7):673-80.
2007: Subramanian K Vadivel; Sundararaman Vardarajan; Richard I Duclos; JodiAnne T Wood; Jianxin Guo; Alexandros Makriyannis
Conformationally constrained analogues of 2-arachidonoylglycerol.
Bioorganic & medicinal chemistry letters 2007;17(21):5959-63.
2007: E J Rahn; A Makriyannis; A G Hohmann
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
British journal of pharmacology 2007;152(5):765-77.
2007: David R Janero; Alexandros Makriyannis
Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.
Current psychiatry reports 2007;9(5):365-73.
2007: David A Karanian; Sanjida L Karim; JodiAnne T Wood; John S Williams; Sonyuan Lin; Alexandros Makriyannis; Ben A Bahr
Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage.
The Journal of pharmacology and experimental therapeutics 2007;322(3):1059-66.
2007: Demetris P Papahatjis; Victoria R Nahmias; Spyros P Nikas; Thanos Andreou; Shakiru O Alapafuja; Andrew Tsotinis; Jianxin Guo; Pusheng Fan; Alexandros Makriyannis
C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols.
Journal of medicinal chemistry 2007;50(17):4048-60.
2007: John Williams; JodiAnne Wood; Lakshmipathi Pandarinathan; David A Karanian; Ben A Bahr; Paul Vouros; Alexandros Makriyannis
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS.
Analytical chemistry 2007;79(15):5582-93.
2007: John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.
Physiology & behavior 2007;91(4):383-8.
2007: Nikolai Zvonok; Suma Yaddanapudi; John Williams; Shujia Dai; Keling Dong; Tomas Rejtar; Barry L Karger; Alexandros Makriyannis
Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor.
Journal of proteome research 2007;6(6):2068-79.
2007: Ankur Kapur; Dow P Hurst; Daniel Fleischer; Rob Whitnell; Ganesh A Thakur; Alexandros Makriyannis; Patricia H Reggio; Mary E Abood
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7.
Molecular pharmacology 2007;71(6):1512-24.
2007: Marcello Solinas; Gianluigi Tanda; Zuzana Justinova; Carrie E Wertheim; Sevil Yasar; Daniele Piomelli; Subramanian K Vadivel; Alexandros Makriyannis; Steven R Goldberg
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
The Journal of pharmacology and experimental therapeutics 2007;321(1):370-80.
2007: Shuxian Jiang; Yigong Fu; John Williams; Jodianne Wood; Lakshmipathi Pandarinathan; Shiri Avraham; Alexandros Makriyannis; Shalom Avraham; Hava Karsenty Avraham
Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells.
PloS one 2007;2(7):e641.
2007: T Gutierrez; J N Farthing; A M Zvonok; A Makriyannis; A G Hohmann
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
British journal of pharmacology 2007;150(2):153-63.
2006: Torbjörn U C Järbe; Richard J Lamb; Qian Liu; Alexandros Makriyannis
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).
Psychopharmacology 2006;188(3):315-23.
2006: Maria Koufaki; Christina Kiziridi; Panagiota Papazafiri; Athanasios Vassilopoulos; Andràs Varró; Zsolt Nagy; Attila Farkas; Alexandros Makriyannis
Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores.
Bioorganic & medicinal chemistry 2006;14(19):6666-78.
2006: T U C Järbe; T Ross; N V DiPatrizio; L Pandarinathan; A Makriyannis
Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.
Pharmacology, biochemistry, and behavior 2006;85(1):243-52.
2006: Kathline Kim; Dan H Moore; Alexandros Makriyannis; Mary E Abood
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.
European journal of pharmacology 2006;542(1-3):100-5.
2006: Jasbeer Dhawan; Hongfeng Deng; S John Gatley; Alexandros Makriyannis; Tolulope Akinfeleye; Magalie Bruneus; Alexis A Dimaio; Andrew N Gifford
Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
Synapse (New York, N.Y.) 2006;60(2):93-101.
2006: Mohab M Ibrahim; Megan L Rude; Nicola J Stagg; Heriberto P Mata; Josephine Lai; Todd W Vanderah; Frank Porreca; Nancy E Buckley; Alexandros Makriyannis; T Philip Malan
CB2 cannabinoid receptor mediation of antinociception.
Pain 2006;122(1-2):36-42.
2006: Ben A Bahr; David A Karanian; Sagar S Makanji; Alexandros Makriyannis
Targeting the endocannabinoid system in treating brain disorders.
Expert opinion on investigational drugs 2006;15(4):351-65.
2006: Demetris P Papahatjis; Victoria R Nahmias; Thanos Andreou; Pusheng Fan; Alexandros Makriyannis
Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
Bioorganic & medicinal chemistry letters 2006;16(6):1616-20.
2006: Peter J McLaughlin; Liu Qian; JodiAnne T Wood; Ania Wisniecki; Keisha M Winston; Lynn A Swezey; Keita Ishiwari; Adrienne J Betz; Lakshmipathi Pandarinathan; Wei Xu; et al.
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
Pharmacology, biochemistry, and behavior 2006;83(3):396-402.
2006: Jian-Zhong Chen; Xiu-Wen Han; Qian Liu; Alexandros Makriyannis; Junmei Wang; Xiang-Qun Xie
3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Journal of medicinal chemistry 2006;49(2):625-36.
2006: John Williams; Lakshmipathi Pandarinathan; JodiAnne Wood; Paul Vouros; Alexandros Makriyannis
Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis.
The AAPS journal 2006;8(4):E655-60.
2006: Dai Lu; V Kiran Vemuri; Richard I Duclos; Alexandros Makriyannis
The cannabinergic system as a target for anti-inflammatory therapies.
Current topics in medicinal chemistry 2006;6(13):1401-26.
2006: Spiro Pavlopoulos; Ganesh A Thakur; Spyros P Nikas; Alexandros Makriyannis
Cannabinoid receptors as therapeutic targets.
Current pharmaceutical design 2006;12(14):1751-69.
2006: Ganesh A Thakur; Spyros P Nikas; Richard I Duclos; Alexandros Makriyannis
Methods for the synthesis of cannabinergic ligands.
Methods in molecular medicine 2006;123():113-48.
2006: Torbjörn U C Järbe; Quian Liu; Alexandros Makriyannis
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Psychopharmacology 2006;184(1):36-45.
2005: Ganesh A Thakur; Richard I Duclos; Alexandros Makriyannis
Natural cannabinoids: templates for drug discovery.
Life sciences 2005;78(5):454-66.
2005: Robert P Picone; Atmaram D Khanolkar; Wei Xu; Lionel A Ayotte; Ganesh A Thakur; Dow P Hurst; Mary E Abood; Patricia H Reggio; Donna J Fournier; Alexandros Makriyannis
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor.
Molecular pharmacology 2005;68(6):1623-35.
2005: Marcello Solinas; Leigh V Panlilio; Gianluigi Tanda; Alexandros Makriyannis; Stephanie A Matthews; Steven R Goldberg
Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(11):2046-57.
2005: Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; et al.
Identification and functional characterization of brainstem cannabinoid CB2 receptors.
Science (New York, N.Y.) 2005;310(5746):329-32.
2005: Chen Li; Wei Xu; Subramanian K Vadivel; Pusheng Fan; Alexandros Makriyannis
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor.
Journal of medicinal chemistry 2005;48(20):6423-9.
2005: Hongfeng Deng; Andrew N Gifford; Alexander M Zvonok; Guangjian Cui; Xiuyan Li; Pusheng Fan; Jeffrey R Deschamps; Judith L Flippen-Anderson; S John Gatley; Alexandros Makriyannis
Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
Journal of medicinal chemistry 2005;48(20):6386-92.
2005: P J McLaughlin; C M Brown; K M Winston; G Thakur; D Lu; A Makriyannis; J D Salamone
The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats.
Behavioural pharmacology 2005;16(5-6):477-86.
2005: Alexandros Makriyannis; Xiaoyu Tian; Jianxin Guo
How lipophilic cannabinergic ligands reach their receptor sites.
Prostaglandins & other lipid mediators 2005;77(1-4):210-8.
2005: W Xu; S A Filppula; R Mercier; S Yaddanapudi; S Pavlopoulos; J Cai; W M Pierce; A Makriyannis
Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system.
The journal of peptide research : official journal of the American Peptide Society 2005;66(3):138-50.
2005: David A Karanian; Queenie B Brown; Alexandros Makriyannis; Therese A Kosten; Ben A Bahr
Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(34):7813-20.
2005: Xiaoyu Tian; Jianxin Guo; Fenmei Yao; De-Ping Yang; Alexandros Makriyannis
The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer.
The Journal of biological chemistry 2005;280(33):29788-95.
2005: Alexandros Makriyannis; Jianxin Guo; Xiaoyu Tian
Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer.
Life sciences 2005;77(14):1605-11.
2005: Charikleia Souli; Nicolaos Avlonitis; Theodora Calogeropoulou; Andrew Tsotinis; Gábor Maksay; Tímea Bíró; Aggeliki Politi; Thomas Mavromoustakos; Alexandros Makriyannis; Heribert Reis; et al.
Novel 17beta-substituted conformationally constrained neurosteroids that modulate GABA A receptors.
Journal of medicinal chemistry 2005;48(16):5203-14.
2005: Karin Woelkart; Wei Xu; Ying Pei; Alexandros Makriyannis; Robert P Picone; Rudolf Bauer
The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.
Planta medica 2005;71(8):701-5.
2005: Dai Lu; Zhaoxing Meng; Ganesh A Thakur; Pusheng Fan; John Steed; Cindy L Tartal; Dow P Hurst; Patricia H Reggio; Jeffrey R Deschamps; Damon A Parrish; et al.
Adamantyl cannabinoids: a novel class of cannabinergic ligands.
Journal of medicinal chemistry 2005;48(14):4576-85.
2005: Ganesh A Thakur; Spyros P Nikas; Alexandros Makriyannis
CB1 cannabinoid receptor ligands.
Mini reviews in medicinal chemistry 2005;5(7):631-40.
2005: P J McLaughlin; K M Winston; C L Limebeer; L A Parker; A Makriyannis; J D Salamone
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.
Psychopharmacology 2005;180(2):286-93.
2005: Alexandros Makriyannis; Raphael Mechoulam; Daniele Piomelli
Therapeutic opportunities through modulation of the endocannabinoid system.
Neuropharmacology 2005;48(8):1068-71.
2005: Peter J McLaughlin; Dai Lu; Keisha M Winston; Ganesh Thakur; Lynn A Swezey; Alexandros Makriyannis; John D Salamone
Behavioral effects of the novel cannabinoid full agonist AM 411.
Pharmacology, biochemistry, and behavior 2005;81(1):78-88.
2005: Zizhong Li; Andrew Gifford; Qian Liu; Rajesh Thotapally; Yu-Shin Ding; Alexandros Makriyannis; S John Gatley
Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds.
Nuclear medicine and biology 2005;32(4):361-6.
2005: Mohab M Ibrahim; Frank Porreca; Josephine Lai; Phillip J Albrecht; Frank L Rice; Alla Khodorova; Gudarz Davar; Alexandros Makriyannis; Todd W Vanderah; Heriberto P Mata; et al.
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(8):3093-8.
2005: Gregory Choi; Jianxin Guo; Alexandros Makriyannis
The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism.
Biochimica et biophysica acta 2005;1668(1):1-9.
2005: David A Karanian; Queenie B Brown; Alexandros Makriyannis; Ben A Bahr
Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus.
European journal of pharmacology 2005;508(1-3):47-56.
2005: G A Thakur; S P Nikas; C Li; A Makriyannis
Structural requirements for cannabinoid receptor probes.
Handbook of experimental pharmacology 2005;(168):209-46.
2004: S Filppula; S Yaddanapudi; R Mercier; W Xu; S Pavlopoulos; A Makriyannis
Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system.
The journal of peptide research : official journal of the American Peptide Society 2004;64(6):225-36.
2004: A G Nackley; A M Zvonok; A Makriyannis; A G Hohmann
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation.
Journal of neurophysiology 2004;92(6):3562-74.
2004: Torbjörn U C Järbe; Michele Y Harris; Chen Li; Qian Liu; Alexandros Makriyannis
Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.
Psychopharmacology 2004;177(1-2):35-45.
2004: T U C Järbe; N V DiPatrizio; D Lu; A Makriyannis
(-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats.
Behavioural pharmacology 2004;15(7):517-21.
2004: Paul W Czoty; Chinnasamy R Ramanathan; Nicole H Mutschler; Alexandros Makriyannis; Jack Bergman
Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors.
The Journal of pharmacology and experimental therapeutics 2004;311(2):720-7.
2004: Paul W Czoty; Alexandros Makriyannis; Jack Bergman
Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys.
Psychopharmacology 2004;175(2):170-8.
2004: Terry Luk; Wenzhen Jin; Alexander Zvonok; Dai Lu; Xin-Zhong Lin; Charles Chavkin; Alexandros Makriyannis; Ken Mackie
Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist.
British journal of pharmacology 2004;142(3):495-500.
2004: Andrea G Hohmann; Jesse N Farthing; Alexander M Zvonok; Alexandros Makriyannis
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
The Journal of pharmacology and experimental therapeutics 2004;308(2):446-53.
2004: M N Arizzi; K M Cervone; J E Aberman; A Betz; Q Liu; S Lin; A Makriyannis; J D Salamone
Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide.
Life sciences 2004;74(8):1001-11.
2004: Spyros P Nikas; Jolanta Grzybowska; Demetris P Papahatjis; Avgui Charalambous; Ali R Banijamali; Ravi Chari; Pusheng Fan; Therapia Kourouli; Sonyuan Lin; Albert J Nitowski; et al.
The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model.
The AAPS journal 2004;6(4):e30.
2003: P J McLaughlin; K Winston; L Swezey; A Wisniecki; J Aberman; D J Tardif; A J Betz; K Ishiwari; A Makriyannis; J D Salamone
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.
Behavioural pharmacology 2003;14(8):583-8.
2003: Maria Koufaki; Theodora Calogeropoulou; Eleni Rekka; Michael Chryselis; Panagiota Papazafiri; Catherine Gaitanaki; Alexandros Makriyannis
Bifunctional agents for reperfusion arrhythmias: novel hybrid vitamin E/class I antiarrhythmics.
Bioorganic & medicinal chemistry 2003;11(23):5209-19.
2003: Jianxin Guo; Spiro Pavlopoulos; Xiaoyu Tian; Dai Lu; Spyros P Nikas; De-Ping Yang; Alexandros Makriyannis
Conformational study of lipophilic ligands in phospholipid model membrane systems by solution NMR.
Journal of medicinal chemistry 2003;46(23):4838-46.
2003: Aline Quartilho; Heriberto P Mata; Mohab M Ibrahim; Todd W Vanderah; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
Anesthesiology 2003;99(4):955-60.
2003: Mohab M Ibrahim; Hongfeng Deng; Alexander Zvonok; Debra A Cockayne; Joyce Kwan; Heriberto P Mata; Todd W Vanderah; Josephine Lai; Frank Porreca; Alexandros Makriyannis; et al.
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(18):10529-33.
2003: Demetris P Papahatjis; Spyros P Nikas; Therapia Kourouli; Ravi Chari; Wei Xu; Roger G Pertwee; Alexandros Makriyannis
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
Journal of medicinal chemistry 2003;46(15):3221-9.
2003: Torbjörn U C Järbe; Nicholas V DiPatrizio; Chen Li; Alexandros Makriyannis
The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats.
Pharmacology, biochemistry, and behavior 2003;75(4):809-21.
2003: Torbjörn U C Järbe; Richard J Lamb; Qian Liu; Alexandros Makriyannis
(R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
European journal of pharmacology 2003;466(1-2):121-7.
2003: Isabel Lastres-Becker; Rosario de Miguel; Luciano De Petrocellis; Alexandros Makriyannis; Vincenzo Di Marzo; Javier Fernández-Ruiz
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Journal of neurochemistry 2003;84(5):1097-109.
2003: Nikos Avlonitis; Eleni Lekka; Anastasia Detsi; Maria Koufaki; Theodora Calogeropoulou; Efi Scoulica; Eleni Siapi; Ioanna Kyrikou; Thomas Mavromoustakos; Andrew Tsotinis; et al.
Antileishmanial ring-substituted ether phospholipids.
Journal of medicinal chemistry 2003;46(5):755-67.
2003: T Philip Malan; Mohab M Ibrahim; Josephine Lai; Todd W Vanderah; Alexandros Makriyannis; Frank Porreca
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?
Current opinion in pharmacology 2003;3(1):62-7.
2003: Chester Chu; Arun Ramamurthy; Alexandros Makriyannis; Marcus A Tius
Synthesis of covalent probes for the radiolabeling of the cannabinoid receptor.
The Journal of organic chemistry 2003;68(1):55-61.
2003: A G Nackley; A Makriyannis; A G Hohmann
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
Neuroscience 2003;119(3):747-57.
2002: Ganesh A Thakur; Sonya L Palmer; Paul E Harrington; Ioanna A Stergiades; Marcus A Tius; Alexandros Makriyannis
Enantiomeric resolution of a novel chiral cannabinoid receptor ligand.
Journal of biochemical and biophysical methods 2002;54(1-3):415-22.
2002: T Philip Malan; Mohab M Ibrahim; Todd W Vanderah; Alexandros Makriyannis; Frank Porreca
Inhibition of pain responses by activation of CB(2) cannabinoid receptors.
Chemistry and physics of lipids 2002;121(1-2):191-200.
2002: Andrew N Gifford; Alexandros Makriyannis; Nora D Volkow; S John Gatley
In vivo imaging of the brain cannabinoid receptor.
Chemistry and physics of lipids 2002;121(1-2):65-72.
2002: Sonya L Palmer; Ganesh A Thakur; Alexandros Makriyannis
Cannabinergic ligands.
Chemistry and physics of lipids 2002;121(1-2):3-19.
2002: Demetris P Papahatjis; Spyros P Nikas; Thanos Andreou; Alexandros Makriyannis
Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols.
Bioorganic & medicinal chemistry letters 2002;12(24):3583-6.
2002: R P Picone; D J Fournier; A Makriyannis
Ligand based structural studies of the CB1 cannabinoid receptor.
The journal of peptide research : official journal of the American Peptide Society 2002;60(6):348-56.
2002: Herbert Schuel; Lani J Burkman; Jack Lippes; Kent Crickard; Mary C Mahony; Andrea Giuffrida; Robert P Picone; Alexandros Makriyannis
Evidence that anandamide-signaling regulates human sperm functions required for fertilization.
Molecular reproduction and development 2002;63(3):376-87.
2002: Andreas Goutopoulos; Alexandros Makriyannis
From cannabis to cannabinergics: new therapeutic opportunities.
Pharmacology & therapeutics 2002;95(2):103-17.
2002: Brian Gardner; Li X Zu; Sherven Sharma; Qian Liu; Alexandros Makriyannis; Donald P Tashkin; Steven M Dubinett
Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta.
Biochemical and biophysical research communications 2002;290(1):91-6.
2001: S Lin; R I Duclos; A Makriyannis
Preparation of optically pure 4-(hydroxymethyl)-2-pentadecyl-1,3-dioxolanes and their corresponding phosphodiester ether lipid derivatives.
Chemistry and physics of lipids 2001;113(1-2):111-22.
2001: T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
CB2 cannabinoid receptor-mediated peripheral antinociception.
Pain 2001;93(3):239-45.
2001: T U Järbe; R J Lamb; S Lin; A Makriyannis
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Psychopharmacology 2001;156(4):369-80.
2001: A Goutopoulos; P Fan; A D Khanolkar; X Q Xie; S Lin; A Makriyannis
Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability.
Bioorganic & medicinal chemistry 2001;9(7):1673-84.
2001: T Mavromoustakos; T Calogeropoulou; M Koufaki; A Kolocouris; I Daliani; C Demetzos; Z Meng; A Makriyannis; J Balzarini; E De Clercq
Ether phospholipid-AZT conjugates possessing anti-HIV and antitumor cell activity. Synthesis, conformational analysis, and study of their thermal effects on membrane bilayers.
Journal of medicinal chemistry 2001;44(11):1702-9.
2001: I I Simoneau; M S Hamza; H P Mata; E M Siegel; T W Vanderah; F Porreca; A Makriyannis; T P Malan
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets.
Anesthesiology 2001;94(5):882-7.
2000: M Cosenza; A N Gifford; S J Gatley; B Pyatt; Q Liu; A Makriyannis; N D Volkow
Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281.
Synapse (New York, N.Y.) 2000;38(4):477-82.
2000: A D Khanolkar; S L Palmer; A Makriyannis
Molecular probes for the cannabinoid receptors.
Chemistry and physics of lipids 2000;108(1-2):37-52.
2000: P E Harrington; I A Stergiades; J Erickson; A Makriyannis; M A Tius
Synthesis of functionalized cannabinoids.
The Journal of organic chemistry 2000;65(20):6576-82.
2000: S L Palmer; A D Khanolkar; A Makriyannis
Natural and synthetic endocannabinoids and their structure-activity relationships.
Current pharmaceutical design 2000;6(13):1381-97.
2000: R J Lamb; T U Järbe; A Makriyannis; S Lin; A Goutopoulos
Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.
European journal of pharmacology 2000;398(2):251-8.
2000: T U Järbe; R J Lamb; S Lin; A Makriyannis
Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication.
Behavioural pharmacology 2000;11(1):81-6.
1999: A N Gifford; M Bruneus; S Lin; A Goutopoulos; A Makriyannis; N D Volkow; S J Gatley
Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374).
European journal of pharmacology 1999;383(1):9-14.
1999: X Q Xie; X W Han; J Z Chen; M Eissenstat; A Makriyannis
High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2.
Journal of medicinal chemistry 1999;42(20):4021-7.
1999: A D Khanolkar; D Lu; P Fan; X Tian; A Makriyannis
Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol.
Bioorganic & medicinal chemistry letters 1999;9(15):2119-24.
1999: J Romero; F Berrendero; L García-Gil; S Y Lin; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide.
Neurochemistry international 1999;34(6):473-82.
1999: D Piomelli; M Beltramo; S Glasnapp; S Y Lin; A Goutopoulos; X Q Xie; A Makriyannis
Structural determinants for recognition and translocation by the anandamide transporter.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(10):5802-7.
1999: W Lang; C Qin; S Lin; A D Khanolkar; A Goutopoulos; P Fan; K Abouzid; Z Meng; D Biegel; A Makriyannis
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
Journal of medicinal chemistry 1999;42(5):896-902.
1999: R Lan; Q Liu; P Fan; S Lin; S R Fernando; D McCallion; R Pertwee; A Makriyannis
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Journal of medicinal chemistry 1999;42(4):769-76.
1999: A N Gifford; M Bruneus; S J Gatley; R Lan; A Makriyannis; N D Volkow
Large receptor reserve for cannabinoid actions in the central nervous system.
The Journal of pharmacology and experimental therapeutics 1999;288(2):478-83.
1999: R Lan; J Gatley; Q Lu; P Fan; S R Fernando; N D Volkow; R Pertwee; A Makriyannis
Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
AAPS pharmSci 1999;1(2):E4.
1999: A D Khanolkar; A Makriyannis
Structure-activity relationships of anandamide, an endogenous cannabinoid ligand.
Life sciences 1999;65(6-7):607-16.
1999: S González; J Romero; R de Miguel; I Lastres-Becker; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.
Life sciences 1999;65(3):327-36.
1998: S Lin; A D Khanolkar; P Fan; A Goutopoulos; C Qin; D Papahadjis; A Makriyannis
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Journal of medicinal chemistry 1998;41(27):5353-61.
1998: T U Järbe; R J Lamb; A Makriyannis; S Lin; A Goutopoulos
Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats.
Psychopharmacology 1998;140(4):519-22.
1998: R de Miguel; J Romero; R M Muñoz; L García-Gil; S González; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs.
Biochemical pharmacology 1998;56(10):1331-8.
1998: D J Drake; R S Jensen; J Busch-Petersen; J K Kawakami; M Concepcion Fernandez-Garcia; P Fan; A Makriyannis; M A Tius
Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues.
Journal of medicinal chemistry 1998;41(19):3596-608.
1998: C Qin; S Lin; W Lang; A Goutopoulos; S Pavlopoulos; F Mauri; A Makriyannis
Determination of anandamide amidase activity using ultraviolet-active amine derivatives and reverse-phase high-performance liquid chromatography.
Analytical biochemistry 1998;261(1):8-15.
1998: D Carriero; J Aberman; S Y Lin; A Hill; A Makriyannis; J D Salamone
A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing.
Psychopharmacology 1998;137(2):147-56.
1998: D P Papahatjis; T Kourouli; V Abadji; A Goutopoulos; A Makriyannis
Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
Journal of medicinal chemistry 1998;41(7):1195-200.
1998: T U Järbe; R Sheppard; R J Lamb; A Makriyannis; S Lin; A Goutopoulos
Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats.
Behavioural pharmacology 1998;9(2):169-74.
1998: X Q Xie; S Pavlopoulos; C M DiMeglio; A Makriyannis
Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling.
Journal of medicinal chemistry 1998;41(2):167-74.
1998: R S Landsman; A Makriyannis; H Deng; P Consroe; W R Roeske; H I Yamamura
AM630 is an inverse agonist at the human cannabinoid CB1 receptor.
Life sciences 1998;62(9):PL109-13.
1998: S J Gatley; R Lan; N D Volkow; N Pappas; P King; C T Wong; A N Gifford; B Pyatt; S L Dewey; A Makriyannis
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
Journal of neurochemistry 1998;70(1):417-23.
1997: A Calignano; G La Rana; A Makriyannis; S Y Lin; M Beltramo; D Piomelli
Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
European journal of pharmacology 1997;340(2-3):R7-8.
1997: A N Gifford; Y Tang; S J Gatley; N D Volkow; R Lan; A Makriyannis
Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.
Neuroscience letters 1997;238(1-2):84-6.
1997: A Calignano; G La Rana; M Beltramo; A Makriyannis; D Piomelli
Potentiation of anandamide hypotension by the transport inhibitor, AM404.
European journal of pharmacology 1997;337(1):R1-2.
1997: M Beltramo; N Stella; A Calignano; S Y Lin; A Makriyannis; D Piomelli
Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
Science (New York, N.Y.) 1997;277(5329):1094-7.
1997: J J Fernández-Ruiz; R M Muñoz; J Romero; M A Villanua; A Makriyannis; J A Ramos
Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Biochemical pharmacology 1997;53(12):1919-27.
1997: S Lin; R I Duclos; A Makriyannis
Syntheses of 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine (DPPC) and analogs with 13C- and 2H-labeled choline head groups.
Chemistry and physics of lipids 1997;86(2):171-81.
1997: Y Hosohata; R M Quock; K Hosohata; A Makriyannis; P Consroe; W R Roeske; H I Yamamura
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
European journal of pharmacology 1997;321(1):R1-3.
1997: S J Gatley; R Lan; B Pyatt; A N Gifford; N D Volkow; A Makriyannis
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.
Life sciences 1997;61(14):PL 191-7.
1997: K Hosohata; R M Quock; Y Hosohata; T H Burkey; A Makriyannis; P Consroe; W R Roeske; H I Yamamura
AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain.
Life sciences 1997;61(9):PL115-8.
1997: X Q Xie; J Moring; A Makriyannis
Differential scanning calorimetry and small angle x-ray diffraction study of the interaction of (R)-PAF, (R)-ET-18-OME and (R)-Lyso-PAF with model membranes.
Life sciences 1997;61(9):909-23.
1996: T Mavromoustakos; E Theodoropoulou; D P Yang; S Y Lin; M Koufaki; A Makriyannis
The conformational properties of the antineoplastic ether lipid 1-thiohexadecyl-2-O-methyl-S-glycero-3-phosphocholine.
Chemistry and physics of lipids 1996;84(1):21-34.
1996: A D Khanolkar; V Abadji; S Lin; W A Hill; G Taha; K Abouzid; Z Meng; P Fan; A Makriyannis
Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
Journal of medicinal chemistry 1996;39(22):4515-9.
1996: J Busch-Petersen; W A Hill; P Fan; A Khanolkar; X Q Xie; M A Tius; A Makriyannis
Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
Journal of medicinal chemistry 1996;39(19):3790-6.
1996: A Tsotinis; T Calogeropoulou; M Koufaki; C Souli; J Balzarini; E De Clercq; A Makriyannis
Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine.
Journal of medicinal chemistry 1996;39(17):3418-22.
1996: X Xie; S Lin; J Moring; A Makriyannis
Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-Lyso-PAF and the antineoplastic (R)-ET-18-OMe.
Biochimica et biophysica acta 1996;1283(1):111-8.
1996: S J Gatley; A N Gifford; N D Volkow; R Lan; A Makriyannis
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
European journal of pharmacology 1996;307(3):331-8.
1996: M Koufaki; V Polychroniou; T Calogeropoulou; A Tsotinis; M Drees; H H Fiebig; S LeClerc; H R Hendriks; A Makriyannis
Alkyl and alkoxyethyl antineoplastic phospholipids.
Journal of medicinal chemistry 1996;39(13):2609-14.
1996: W Lang; C Qin; W A Hill; S Lin; A D Khanolkar; A Makriyannis
High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes.
Analytical biochemistry 1996;238(1):40-5.
1996: T Mavromoustakos; E Theodoropoulou; D Papahatjis; T Kourouli; D P Yang; M Trumbore; A Makriyannis
Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction.
Biochimica et biophysica acta 1996;1281(2):235-44.
1996: X Q Xie; L S Melvin; A Makriyannis
The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940.
The Journal of biological chemistry 1996;271(18):10640-7.
1996: T Mavromoustakos; D P Yang; A Makriyannis
Topography and thermotropic properties of cannabinoids in brain sphingomyelin bilayers.
Life sciences 1996;59(23):1969-79.
1996: J Romero; E García-Palomero; S Y Lin; J A Ramos; A Makriyannis; J J Fernández-Ruiz
Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.
Life sciences 1996;58(15):1249-57.
1995: T Mavromoustakos; D P Yang; A Makriyannis
Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation.
Biochimica et biophysica acta 1995;1239(2):257-64.
1995: T Mavromoustakos; D P Yang; A Makriyannis
Small angle X-ray diffraction and differential scanning calorimetric studies on O-methyl-(-)-delta 8-tetrahydrocannabinol and its 5' iodinated derivative in membrane bilayers.
Biochimica et biophysica acta 1995;1237(2):183-8.
1995: R G Pertwee; S R Fernando; G Griffin; V Abadji; A Makriyannis
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations.
European journal of pharmacology 1995;272(1):73-8.
1995: M A Tius; W A Hill; X L Zou; J Busch-Petersen; J K Kawakami; M C Fernandez-Garcia; D J Drake; V Abadji; A Makriyannis
Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain.
Life sciences 1995;56(23-24):2007-12.
1995: X Q Xie; M Eissenstat; A Makriyannis
Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids.
Life sciences 1995;56(23-24):1963-70.
1995: K L Morse; D J Fournier; X Li; J Grzybowska; A Makriyannis
A novel electrophilic high affinity irreversible probe for the cannabinoid receptor.
Life sciences 1995;56(23-24):1957-62.
1995: R Pertwee; G Griffin; S Fernando; X Li; A Hill; A Makriyannis
AM630, a competitive cannabinoid receptor antagonist.
Life sciences 1995;56(23-24):1949-55.
1994: R I Duclos; H H Chia; O H Abdelmageed; H Esber; D J Fournier; A Makriyannis
Syntheses of racemic and nearly optically pure ether lipids and evaluation of in vitro antineoplastic activities.
Journal of medicinal chemistry 1994;37(24):4147-54.
1994: Y Guo; V Abadji; K L Morse; D J Fournier; X Li; A Makriyannis
(-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain.
Journal of medicinal chemistry 1994;37(23):3867-70.
1994: D Yin; A D Khanolkar; A Makriyannis; M Froimowitz
Chiral resolution of 1,3-dimethyl-4-phenylpiperidine derivatives using high-performance liquid chromatography with a chiral stationary phase.
Journal of chromatography. A 1994;678(1):176-9.
1994: T Mavromoustakos; D P Yang; A Makriyannis
Topography of alphaxalone and delta 16-alphaxalone in membrane bilayers containing cholesterol.
Biochimica et biophysica acta 1994;1194(1):69-74.
1994: G Yan; D Yin; A D Khanolkar; D R Compton; B R Martin; A Makriyannis
Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist.
Journal of medicinal chemistry 1994;37(16):2619-22.
1994: V Abadji; S Lin; G Taha; G Griffin; L A Stevenson; R G Pertwee; A Makriyannis
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.
Journal of medicinal chemistry 1994;37(12):1889-93.
1994: X Q Xie; D P Yang; L S Melvin; A Makriyannis
Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling.
Journal of medicinal chemistry 1994;37(10):1418-26.
1993: B R Martin; D R Compton; S F Semus; S Lin; G Marciniak; J Grzybowska; A Charalambous; A Makriyannis
Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.
Pharmacology, biochemistry, and behavior 1993;46(2):295-301.
1993: C M DiMeglio; M Froimowitz; A Makriyannis
Conformational analysis of the opioid phenylmorphan and its 9 alpha-methyl analogue in solution using high-resolution nuclear magnetic resonance spectroscopy.
Pharmaceutical research 1993;10(8):1200-5.
1993: A Makriyannis; C M DiMeglio; A P DeJong; S el-Khateeb
Hallucinogenic receptor models: interaction of imidazolium chloride with amphetamine analogs.
Molecular pharmacology 1993;43(1):78-83.
1993: D P Yang; T Mavromoustakos; A Makriyannis
Small angle X-ray diffraction studies of (-)-delta 8-tetrahydrocannabinol and its O-methyl analog in membranes.
Life sciences 1993;53(7):PL117-22.
1993: A Makriyannis
Probes for the cannabinoid sites of action.
NIDA research monograph 1993;134():253-67.
1992: M Froimowitz; C M DiMeglio; A Makriyannis
Conformational preferences of the kappa-selective opioid agonist U50488. A combined molecular mechanics and nuclear magnetic resonance study.
Journal of medicinal chemistry 1992;35(17):3085-94.
1992: A Charalambous; G Yan; D B Houston; A C Howlett; D R Compton; B R Martin; A Makriyannis
5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor.
Journal of medicinal chemistry 1992;35(16):3076-9.
1992: D P Yang; T Mavromoustakos; K Beshah; A Makriyannis
Amphipathic interactions of cannabinoids with membranes. A comparison between delta 8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR.
Biochimica et biophysica acta 1992;1103(1):25-36.
1991: D P Yang; A Banijamali; A Charalambous; G Marciniak; A Makriyannis
Solid state 2H-NMR as a method for determining the orientation of cannabinoid analogs in membranes.
Pharmacology, biochemistry, and behavior 1991;40(3):553-7.
1991: T Mavromoustakos; D P Yang; W Broderick; D Fournier; A Makriyannis
Small angle x-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes.
Pharmacology, biochemistry, and behavior 1991;40(3):547-52.
1991: A Charalambous; S Lin; G Marciniak; A Banijamali; F L Friend; D R Compton; B R Martin; A Makriyannis
Pharmacological evaluation of halogenated delta 8-THC analogs.
Pharmacology, biochemistry, and behavior 1991;40(3):509-12.
1991: A Charalambous; G Marciniak; C Y Shiue; S L Dewey; D J Schlyer; A P Wolf; A Makriyannis
PET studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta 8-THC.
Pharmacology, biochemistry, and behavior 1991;40(3):503-7.
1991: A Makriyannis; C M DiMeglio; S W Fesik
Anesthetic steroid mobility in model membrane preparations as examined by high-resolution 1H and 2H NMR spectroscopy.
Journal of medicinal chemistry 1991;34(5):1700-3.
1991: S H Burstein; C A Audette; A Charalambous; S A Doyle; Y Guo; S A Hunter; A Makriyannis
Detection of cannabinoid receptors by photoaffinity labelling.
Biochemical and biophysical research communications 1991;176(1):492-7.
1991: A Makriyannis; D P Yang; T Mavromoustakos
Combined use of solid-state nuclear magnetic resonance spectroscopy, small-angle x-ray diffraction, and differential scanning calorimetry in studies of cannabinoid: membrane interactions.
NIDA research monograph 1991;112():106-28.
1990: D L Melchior; A Carruthers; A Makriyannis; R I Duclos; O H Abdel-Mageed
Alterations in red blood cell sugar transport by nanomolar concentrations of alkyl lysophospholipid.
Biochimica et biophysica acta 1990;1028(1):1-8.
1990: A Makriyannis; D P Yang; R G Griffin; S K Das Gupta
The perturbation of model membranes by (-)-delta 9-tetrahydrocannabinol. Studies using solid-state 2H- and 13C-NMR.
Biochimica et biophysica acta 1990;1028(1):31-42.
1990: T Mavromoustakos; D P Yang; A Charalambous; L G Herbette; A Makriyannis
Study of the topography of cannabinoids in model membranes using X-ray diffraction.
Biochimica et biophysica acta 1990;1024(2):336-44.
1990: O H Abdelmageed; R I Duclos; E Abushanab; A Makriyannis
Chirospecific syntheses of 2H- and 13C-labeled 1-O-alkyl-2-O-alkyl'-sn-glycero-3-phosphoethanolamines and 1-O-alkyl-2-O-alkyl'-sn-glycero-3-phosphocholines.
Chemistry and physics of lipids 1990;54(1):49-59.
1990: A Makriyannis; D P Yang; T Mavromoustakos
The molecular features of membrane perturbation by anaesthetic steroids: a study using differential scanning calorimetry, small angle X-ray diffraction and solid state 2H NMR.
Ciba Foundation symposium 1990;153():172-84; discussion 185-9.
1990: A Makriyannis; R S Rapaka
The molecular basis of cannabinoid activity.
Life sciences 1990;47(24):2173-84.
1989: A Makriyannis; A Banijamali; H C Jarrell; D P Yang
The orientation of (-)-delta 9-tetrahydrocannabinol in DPPC bilayers as determined from solid-state 2H-NMR.
Biochimica et biophysica acta 1989;986(1):141-5.
1989: R W Kriwacki; A Makriyannis
The conformational analysis of delta 9- and delta 9,11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy.
Molecular pharmacology 1989;35(4):495-503.
1988: C J Van der Schyf; T Mavromoustakos; A Makriyannis
The conformation of (-) 8 alpha and (-) 8 beta-hydroxy-delta 9-tetrahydrocannabinols and their interactions with model membranes.
Life sciences 1988;42(22):2231-9.
1987: A Makriyannis; R S Rapaka
The medicinal chemistry of cannabinoids: an overview.
NIDA research monograph 1987;79():204-10.
1987: A Makriyannis; A Banijamali; C Van der Schyf; H Jarrell
Interactions of cannabinoids with membranes. The role of cannabinoid stereochemistry and absolute configuration and the orientation of delta-9-THC in the membrane bilayer.
NIDA research monograph 1987;79():123-33.